← All stocks

Edgewise Therapeutics, Inc.

EWTX Net buying

CIK 0001710072 #1406 in the set updated 18 Sep 2026

Bought (120 mo)

$79.04M

out of their own pocket, the only kind of buying there is

Sold (120 mo)

$46.45M

$506.73K on a plan · $38.09M straight out of an exercise

Sold at will

$7.86M

60 of 145 sales

Net

+$32.59M

+$71.18M against sales at will

By person

15 insiders · 172 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

ORBIMED ADVISORS LLC entity

Director

$26.74M (7)

—

+$26.74M

443,792

0.4086%

$19.26M

—

Thompson Peter A.

Director

$26.74M (7)

—

+$26.74M

443,792

0.4086%

$19.26M

—

Russell Alan J

Chief Scientific Officer

—

$23.50M (54) scheduled

−$23.50M

31,466

0.0290%

$1.37M

−88.5%

Novo Holdings A/S entity

10% owner

$15.00M (2)

—

+$15.00M

6,071,703

5.59%

$263.55M

—

Flynn James E

10% owner

$10.00M (1)

—

+$10.00M

3,933,137

3.62%

$170.72M

—

Donovan Joanne M.

CMO

—

$5.74M (17) scheduled

−$5.74M

8,625

0.0079%

$374.38K

−27.9%

Carruthers R Michael

Chief Financial Officer

—

$5.09M (9) scheduled

−$5.09M

86,162

0.0793%

$3.74M

+682.2%

MOORE JOHN R

General Counsel

—

$4.45M (35) scheduled

−$4.45M

17,697

0.0163%

$768.16K

+241.2%

Edris Badreddin

Director

—

$3.40M (5) scheduled

−$3.40M

19,820

0.0182%

$860.32K

0.0%

Derakhshan Behrad

Chief Business Officer

—

$2.05M (13) scheduled

−$2.05M

31,826

0.0293%

$1.38M

+221.9%

KOCH KEVIN

President and CEO

—

$1.34M (10) scheduled

−$1.34M

52,488

0.0483%

$2.28M

—

Semigran Marc

Chief Development Officer

—

$881.92K (2) scheduled

−$881.92K

6,716

0.0062%

$291.52K

0.0%

Fox Jonathan C

Director

$300.36K (2)

—

+$300.36K

24,833

0.0229%

$1.08M

—

ROOT JONATHAN D

Director

$250.00K (1)

—

+$250.00K

15,625

0.0144%

$678.23K

—

Wellington Biomedical Innovation Master Investors (Cayman) I L.P.

10% owner

—

681,812

0.6278%

$29.60M

—

Individual transactions

Insider

Date

Role

Action

Price

Amount

Carruthers R Michael

11 Oct 2024

Chief Financial Officer

Exercised, kept

70,000

$0.71

$49.70K

Carruthers R Michael

22 Jun 2023

Chief Financial Officer

Exercised, kept

10,000

$0.71

$7.10K

Carruthers R Michael

23 May 2022

Chief Financial Officer

Exercised, kept

9,000

$0.71

$6.39K

MOORE JOHN R

21 Jan 2022

General Counsel

Exercised, kept

5,400

$0.71

$3.83K

MOORE JOHN R

28 Dec 2021

General Counsel

Exercised, kept

5,400

$0.71

$3.83K

Russell Alan J

30 Nov 2021

Chief Scientific Officer

Exercised, kept

25,000

$0.45

$11.25K

Russell Alan J

30 Nov 2021

Chief Scientific Officer

Exercised, kept

147,585

$0.18

$26.57K

Show all 172 transactions →

What was left out

Form 4 filings counted 173

Amendments (4/A) skipped 5

Filings about a different issuer 0

Unreadable filings 0

Joint filings 6

Sales on a Rule 10b5-1 plan 2

Sales straight out of an exercise 83

Sales at will 60

Transactions with no price 0

Shares from compensation/vesting 43,853,493

Sales filed before the plan box existed 37

History held since 30 Mar 2021